Silverback Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

Rhea-AI Impact

(Low)

Rhea-AI Sentiment

(Neutral)

Tags

conferences

05/17/2022 - 04:05 PM

SEATTLE--(BUSINESS WIRE)-- Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases, today announced that Silverback management will participate in the H.C. Wainwright 24^th Global Investment Conference from May 23-25, 2022.

Laura Shawver, Ph.D., Silverback’s Chief Executive Officer, will provide a corporate overview on Tuesday, May 24, 2022 at 7:00 AM ET / 4:00 AM PT. The webcast of the presentation will be available on Silverback’s Investor Relations website for 30 days following the event. Members of the Silverback management team will also host investor meetings during the conference.

About Silverback Therapeutics

Silverback Therapeutics, Inc. is a biopharmaceutical company focused on leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered and tissue targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. Silverback’s platform enables the strategic pairing of proprietary payloads that modulate key disease modifying pathways with monoclonal antibodies directed at specific disease sites. Silverback Therapeutics is located in Seattle, Washington. To learn more, visit www.silverbacktx.com.